Literature DB >> 6697640

Renal actions of piretanide and three other "loop" diuretics.

W R McNabb, F H Noormohamed, B A Brooks, A F Lant.   

Abstract

Thirty-nine clearance studies were performed in 17 healthy subjects under conditions of maximal hydration or hydropenia to compare the effects on renal solute and water handling of three sulfamoylbenzoic acid derivatives-piretanide, bumetanide, and furosemide-and the phenoxyacetic acid diuretic ethacrynic acid. Except for furosemide, which caused a 7% fall in effective renal plasma flow (ERPF), and ethacrynic acid, which reduced both the glomerular filtration rate (16%) and ERPF (23%) during maximal hydration, changes in hemodynamics were insignificant. At peak saluresis piretanide induced a mean reduction of -18.3% +/- 4.9% in fractional free-water clearance during hydration and -73.2% +/- 5.9% in fractional free-water reabsorption during hydropenia. The other sulfamoylbenzoates lowered fractional clearance and reabsorption of free water to similar extents, implying a major site of action within the medullary portion of the ascending limb. Ethacrynic acid reduced fractional free-water clearance to a greater degree than did the sulfamoylbenzoates. The mean reduction in fractional free-water reabsorption after ethacrynic acid (71.4% +/- 8.2%) was of the same order as that caused by the sulfamoylbenzoates. Similar excretory maxima for sodium, chloride, potassium, calcium, and magnesium were achieved for all four diuretics. Except for piretanide under hydropenia, sulfamoylbenzoate action did not change urinary pH. Ethacrynic acid consistently lowered urinary pH. During hydration piretanide induced phosphaturia (35.3% +/- 8.8%) and uricosuria (40.9% +/- 9.1%). Both bumetanide and piretanide increased fractional urate clearance during hydropenia (16.7% +/- 5.6% and 34.2% +/- 10.5%). There were no changes in phosphate or urate excretion after ethacrynic acid. Our data support the view that sulfamoylbenzoate diuretics exert additional effects on proximal tubular segments that are not shared by ethacrynic acid. Renal responses to piretanide most closely resemble those to bumetanide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6697640     DOI: 10.1038/clpt.1984.38

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 2.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 3.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

Review 4.  The elderly patient. A special case for diuretic therapy.

Authors:  D E Hyams
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 5.  Diuretic drugs. Progress in clinical pharmacology.

Authors:  A Lant
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 6.  Clinical relevance of drug interactions with lithium.

Authors:  P R Finley; M D Warner; C A Peabody
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

7.  The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.

Authors:  J J Dixey; F H Noormohamed; A F Lant; D A Brewerton
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

8.  Lithium clearance: modification by the loop of Henle in man.

Authors:  J C Atherton; A Doyle; A Gee; R Green; S Gingell; F Nicholls; L Pempkowiak; J Plange-Rhule
Journal:  J Physiol       Date:  1991-06       Impact factor: 5.182

Review 9.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

10.  Acute and long-term renal and metabolic effects of piretanide in congestive cardiac failure.

Authors:  W R McNabb; F H Noormohamed; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.